Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein

0 views • Nov 4, 2021


Author Name


Seth J. Zost

Pavlo Gilchuk

Rita E. Chen

James Brett Case

Joseph X Reidy

Andrew Trivette

Rachel S Nargi

Rachel E Sutton

Elaine C Chen

Elad Binshtein

Swathi Shrihari

Mario Ostrowski

Helen Y Chu

Jonathan E Didier

Keith W MacRenaris

Taylor Jones

Samuel Day

Luke Myers

F. Eun-Hyung Lee

Doan C Nguyen

Ignacio Sanz

David R. Martinez

Ralph S. Baric

Larissa B Thackray

Michael Diamond

Robert H. Carnahan

James E. Crowe

Add New Author

Antibodies are a principal determinant of immunity for most RNA viruses and have promise to reduce infection or disease during major epidemics. The novel coronavirus SARS-CoV-2 has caused a global pandemic with millions of infections and hundreds of thousands of deaths to date1,2. In response, we used a rapid antibody discovery platform to isolate hundreds of human monoclonal antibodies (mAbs) against the SARS-CoV-2 spike (S) protein. We stratify these mAbs into five major classes based on their reactivity to subdomains of S protein as well as their cross-reactivity to SARS-CoV. Many of these mAbs inhibit infection of authentic SARS-CoV-2 virus, with most neutralizing mAbs recognizing the receptor-binding domain (RBD) of S. This work defines sites of vulnerability on SARS-CoV-2 S and demonstrates the speed and robustness of existing antibody discovery methodologies ### Competing Interest Statement R.S.B. has served as a consultant for Takeda and Sanofi Pasteur on issues related to vaccines. M.S.D. is a consultant for Inbios Vir Biotechnology, NGM Biopharmaceuticals, Eli Lilly, and on the Scientific Advisory Board of Moderna, and a recipient of unrelated research grants from Moderna and Emergent BioSolutions. J.E.C. has served as a consultant for Sanofi and is on the Scientific Advisory Boards of CompuVax and Meissa Vaccines, is a recipient of previous unrelated research grants from Moderna and Sanofi and is Founder of IDBiologics, Inc. Vanderbilt University has applied for patents concerning SARS-CoV-2 antibodies that are related to this work. F.E.-H.L., D.C.N., and I.S. are inventors on a patent submitted for the plasmablast survival medium. J.D. and K.W.M. are employees of Berkeley Lights, Inc. All other authors declared no competing interests.

Monoclonal 3 Projects
Coronavirus 15 Projects
SARS-CoV-2 42 Projects
Antibodies 7 Projects
COVID-19 47 Projects
Sars Cov
Sars Cov 3 Projects
Immunology 63 Projects